Acola CEO Gives Online Interview to CEOCast.com.

Business Editors/Health & Medical Writers

HOUSTON--(BUSINESS WIRE)--Nov. 1, 2001

Acola Corp., a Delaware corporation (formerly MegaChain.com, Ltd., OTCBB:MGCC, now OTCBB:ACAC) ("Acola"), announced today that Mr. Robert B. Dillon, president, chief executive officer and director of Acola Corp., gave Mike Wachs, of CEOCast.com, an interview on Oct. 30, 2001 highlighting a discussion of the drug, Anvirzel(TM). He also outlined the formation of Acola Corp., its role as the exclusive distributor of Anvirzel(TM) in Mexico, and Acola Corp.'s direction for the future. An audio of that interview is available on CEOCast.com and will soon be available on Acola Corp.'s Web site at AcolaCorp.com.

Anvirzel(TM) is intended for the treatment of serious illnesses, such as cancer, HIV/AIDS, Hepatitis C and the other viral and autoimmune/inflammatory diseases for which Anvirzel(TM) has shown promise. According to Acola's President and CEO, Robert B. Dillon, "Acola is eagerly looking forward to developing and distributing Anvirzel(TM) in Mexico for all the people who stand to benefit from this drug."

Anvirzel(TM) is an internationally patented (U.S. Patent No. 5,135,745) non-toxic aqueous extract of Nerium Oleander manufactured by Ozelle Pharmaceuticals Inc. in conformity with U.S. FDA Good Manufacturing Practice (GMP) regulations. Anvirzel(TM) has been granted what is believed to be the only compassionate use IND (No. 56826) ever granted by the U.S. FDA, pursuant to which 15 late Stage IV terminal U.S. cancer patients were treated with Anvirzel(TM) demonstrating significant efficacy. Anvirzel(TM) has already been successfully used to treat several hundred cancer and AIDS patients in Ireland, Honduras, Canada and the United States. Anvirzel(TM) has shown, in both foreign patient use and U.S. FDA authorized United States "Compassionate Use" patients, anecdotal evidence of its ability to cause remission of certain cancers, control these diseases and/or minimize their debilitating effects. It is demonstrating itself to be a drug without harmful side effects that, in nearly every instance, provides some early and sustained benefits even to otherwise untreatable patients. Anvirzel(TM) has successfully concluded U.S. FDA Phase I human clinical trials at The Cleveland Clinic Foundation with a published finding of "no dose limiting toxicity."

Ozelle Pharmaceuticals Inc. anticipates initiating Phase II human trials in the U.S. and Ireland in the immediate future. Acola has arranged for expedited trials for Anvirzel(TM) in Mexico and anticipates its general availability in Mexico in 2002.

Acola's executive offices are located in Houston, Texas. Acola presently has 5 employees, most of whom are shareholders.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by Acola or on its behalf. These forward-looking statements are not historical facts, but reflect Acola's current expectations, estimates and projections. All statements contained in the press release which address future operating performance, events or developments that are expected to occur in the future (including statements relating to earnings expectations, sales of assets, or statements expressing general optimism about future operating results) are forward-looking statements. Although Acola believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved. Important factors that could cause actual results to differ materially from those in the forward-looking statements herein include success in marketing Anvirzel(TM) in Mexico, FDA approval of Anvirzel(TM) in the United States, development of Acola's market in Mexico, and conditions of the capital markets and equity markets during the periods covered by the forward-looking statements.